Dispatim

Quick links to important sections

Dispatim

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dispatim

Quick Facts

Property Description
Active ingredient Timolol (as Timolol maleate)
Form Topical Ophthalmic Solution (Eye drops)
Pharmacological Class Beta-Adrenergic Receptor Blocking Agent
General Purpose Reduction of Elevated Intraocular Pressure (IOP)
Origin Synthetic Compound

What Type of Medicine is Dispatim? (Class and Composition)

Dispatim is a prescription-only medicine (Rx) containing Timolol (as the maleate salt) as its sole active ingredient. This synthetic compound is classified within the pharmaceutical category of a non-selective beta-adrenergic receptor blocking agent, widely known as a beta-blocker. This classification means the drug works by influencing adrenergic receptors. The efficacy of Timolol in reducing intraocular pressure is clinically recognized, establishing its prominent role in pressure management.

Dispatim utilizes only this single ingredient, differentiating it from combination products that contain multiple active substances. The compound is noted for its ability to reduce elevated pressure effectively when administered topically.

Form and Therapeutic Goal (Administration and Purpose)

The medicine is supplied for localized use in the eye as a topical ophthalmic solution (eye drops or gel-forming solution). This specific topical ophthalmic delivery system is the defining feature of Dispatim, ensuring the active agent is precisely delivered to the target area. The primary therapeutic goal is the sustained and reliable reduction of elevated intraocular pressure (IOP).

In a typical scenario, Dispatim is used to maintain healthy eye pressure levels over time for adults diagnosed with chronic pressure issues. The pressure-lowering effect is achieved through the compound's localized influence on the ciliary body, resulting in a decrease in the rate of aqueous humor formation, which consequently helps protect the eye's internal structures.

Regulatory References

  1. National Institutes of Health (NIH) DailyMed: Timolol

What side effects are possible with Dispatim?

Possible Side Effects and Safety Information

Dispatim (Timolol Ophthalmic Solution) is associated with both local ocular adverse reactions and potential systemic adverse reactions resulting from absorption into the bloodstream, characteristic of a non-selective beta-adrenergic blocking agent. The safety profile is structured by System-Organ Class to include effects on the eye, heart, respiratory system, and nervous system, as defined in official regulatory documents.


Documented Adverse Reactions

Commonly reported effects (occurring in ge 1/100 to < 1/10 patients) include local symptoms such as burning, stinging, or redness of the eye, and headache. Uncommon effects (ge 1/1,000 to < 1/100) include dizziness and certain visual disturbances.

Rare and serious adverse reactions are documented, primarily involving the cardiac and respiratory systems. These include the potential for cardiac arrest, congestive heart failure, severe bradycardia, and bronchospasm.


Population-Specific Safety Constraints

The medicine is contraindicated by regulatory authorities for individuals with certain pre-existing conditions. These include patients with bronchial asthma or severe chronic obstructive pulmonary disease (COPD) due to the risk of severe respiratory distress, and those with certain heart rhythm abnormalities (e.g., sinus bradycardia, heart block) or overt cardiac failure. For diabetic patients, the drug may mask signs of acute hypoglycemia.

Regulatory safety information notes that systemic absorption is possible, which necessitates caution regarding potential additive systemic effects if used concurrently with oral beta-blockers.

Overdose and Emergency Response

Dispatim Overdose and When to Seek Help

Overdose with Dispatim (Timolol maleate) is officially documented to result from excessive systemic absorption, leading to severe manifestations of beta-adrenergic blockade. Documented clinical presentations include cardiovascular system effects such as abnormally slow heart rate (bradycardia), severe hypotension (low blood pressure), and arrhythmia. Other signs may involve the central nervous system, including dizziness and confusion.

The regulatory profile specifies potential life-threatening outcomes such as cardiac arrest, severe cardiac failure, and bronchospasm, which represents a particularly high risk for individuals with pre-existing bronchospastic disease. Additionally, diabetic patients should be monitored as an overdose may mask the characteristic symptoms of acute hypoglycemia.

In the event of a suspected overdose, immediate medical attention is required. Official government guidance states that emergency medical services must be contacted immediately if the patient exhibits signs of a life-threatening event, including collapse, seizures, or acute difficulty breathing. Treatment focuses on symptomatic and supportive measures, as the official regulatory record indicates that no specific antidote is known for Timolol overdose. The medication must be discontinued immediately if any sign of cardiac failure develops.

Therapeutic Uses of Dispatim

Quick Facts: Dispatim

  • Manages heart rhythm abnormalities (arrhythmias)
  • Used for ventricular and supraventricular arrhythmias
  • Helps manage atrial fibrillation

Dispatim is a medication prescribed to manage and prevent certain heart rhythm abnormalities (arrhythmias). These conditions involve an irregular or abnormal heartbeat, which can affect the heart's ability to circulate blood effectively.

The primary use of Dispatim is in the clinical management of specific ventricular and supraventricular arrhythmias. It is also utilized to help manage and convert atrial fibrillation—a common form of irregular heartbeat—to a normal rhythm, particularly in patients with certain underlying heart conditions like hypertrophic obstructive cardiomyopathy (HOCM). Dispatim works by influencing the heart's electrical signaling, which helps restore a regular heart rhythm and decrease myocardial excitability.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Dispatim

Dispatim (Timolol Maleate Ophthalmic Solution) is approved for use in adults with ocular hypertension or chronic open-angle glaucoma. Eligibility is strictly defined by regulatory documents, which mandate the exclusion of specific populations due to the risk of systemic absorption of the beta-blocker.

Classification Population Status Restrictions/Limitations
Contraindicated Patients with bronchial asthma, a history of asthma, or severe COPD (Chronic Obstructive Pulmonary Disease) [FDA, EMA]. Must not be used in patients with overt cardiac failure, sinus bradycardia, cardiogenic shock, or second/third-degree AV block [FDA, EMA].
Use Not Established Pediatric patients (children and adolescents). Safety and effectiveness have not been established in this age group, requiring extreme caution for use [FDA, EMA].
Not Recommended Patients who are pregnant or breastfeeding. Use is not recommended unless clearly necessary; the drug is known to be excreted into human milk [FDA].
Use with Caution Patients with labile diabetes, first-degree heart block, or myasthenia gravis. Close monitoring is required for patients with mild to moderate COPD, severe peripheral circulatory disturbances, or cerebrovascular insufficiency [EMA, FDA].

The official eligibility profile is structured around absolute contraindications against severe respiratory and cardiac diseases, while use in pregnant, nursing, and pediatric populations is not recommended or not established.

What should I know about interactions with other medicines?

The interaction profile of Dispatim (Timolol Ophthalmic Solution) is defined by both pharmacodynamic and pharmacokinetic interactions, as documented in regulatory labeling.

Pharmacodynamic and Exposure Interactions

Interacting Agents Official Interaction Classification & Outcome
Systemic Beta-Adrenergic Blocking Agents Co-administration may result in additive effects of beta-blockade, both systemic and on intraocular pressure.
Topical Beta-Adrenergic Blocking Agents The concomitant use of two topical beta-adrenergic blocking agents is not recommended.
CYP2D6 Inhibitors (e.g., Quinidine, Fluoxetine, Cimetidine) Pharmacokinetic interaction leading to increased plasma Timolol concentration by reducing systemic clearance.
Oral/Intravenous Calcium Antagonists Additive effects may cause potential atrioventricular conduction disturbances, left ventricular failure, and hypotension.
Antiarrhythmics (e.g., Amiodarone) Potential for additive effects leading to marked bradycardia and/or hypotension.

Administration and Population Notes

When Dispatim is used alongside other topical ophthalmic agents, an administration separation of at least 10 minutes is required to prevent medication wash-out. In diabetic patients receiving insulin or oral hypoglycemic agents, beta-adrenergic blocking agents may mask the signs of acute hypoglycemia, such as tachycardia. Regulatory documents also note that alcohol consumption may result in increased plasma levels of Timolol.

Mechanism of Action

How Dispatim Works

Dispatim's action involves a precise modulation of specific biological signaling pathways, leading to predictable physiological adjustments.


GPCR Signaling Pathway Modulation

Dispatim engages mechanisms that primarily involve G-protein coupled receptor-mediated signaling. It acts as a selective modulator at a distinct GPCR subtype, thereby initiating or suppressing the downstream intracellular signaling sequences. This affects biological systems where specific transmitters or mediators dominate, modifying early molecular steps that results in the altered frequency of effector molecule activation.


Influence on Signaling Network Activity

The drug acts within domains that influence signaling network activity driven by distinct patterns. Dispatim influences feedback regulation within pathways relevant in cascades where multiple layers of pathway activation occur. This modulation of early molecular steps results in reduced secondary messenger accumulation, and subsequently modulates the firing rate of downstream kinases.


Enzyme-Mediated Signaling Modification

Dispatim's mechanism supports the kinetic properties of biological systems by altering enzyme activity that may escalate under certain conditions. It leads to predictable physiological adjustments by targeting mechanisms that regulate the degree of enzyme-mediated signaling. The drug is relevant in systems where targeted pathway adjustment is required, resulting in an overall net decrease in target pathway flux.

Dosage and Administration Information

Administration of Dispatim

Dispatim is an ophthalmic solution intended for topical application to the eyes. Proper administration technique is important to ensure the solution is delivered effectively and to maintain the sterility of the product.

Preparation

Before applying the eye drops, hands should be washed thoroughly with soap and water. If contact lenses are worn, they should generally be removed before using the medication.

Application Technique

To apply the drops, the head should be tilted back slightly while looking upward. Using one hand, the lower eyelid is gently pulled down to create a small pocket. The dropper bottle is held over the eye with the tip pointing downward. It is important to ensure that the tip of the dropper does not touch the eye, eyelashes, eyelids, or any other surface, as this can lead to contamination of the solution.

A single drop is released into the pocket created by the lower eyelid. After the drop is instilled, the eye should be closed gently. To help keep the medication in the eye and reduce systemic absorption, light pressure can be applied to the inner corner of the eye (near the nose) for a brief period.

Using Multiple Eye Medications

If more than one type of eye drop is being used, a sufficient interval of time should be allowed between the application of each medication. This prevents the first drop from being washed out by the second and ensures both are absorbed correctly. If an eye ointment is also being used, it is typically applied after the eye drops.

Bottle Care

The cap should be replaced and tightened immediately after use. The bottle should be stored according to the temperature requirements specified on the product packaging and kept out of the reach of children.

Recent Clinical Evidence

Dispatim: Recent Clinical Evidence

Evidence for use in Elevated Intraocular Pressure

Research exploring Dispatim has involved multiple randomized trials and systematic reviews of pooled trial data, primarily focusing on adults diagnosed with Ocular Hypertension or Primary Open-Angle Glaucoma. The main outcomes studied involved the measurement of Intraocular Pressure (IOP) levels over defined time intervals. Short-term studies, often lasting three to six months, examined changes in IOP compared to placebo, and findings describe the patterns of IOP change observed during these study periods. This initial evidence is part of the broader evidence landscape describing how patients’ pressure levels evolved in the observed populations.

Comparisons with Other Treatment Types

Research has also explored Dispatim’s measured effects when compared to other established medications or utilized as part of a fixed-combination therapy. These studies were conducted to evaluate the measured differences in IOP change between various comparator agents. Findings report that measured changes in IOP differ when Dispatim is compared with other agents, and combination therapies had different IOP measurements recorded than monotherapy.

Long-Term Study Data and Follow-Up

The evidence base includes long-term observational studies and controlled trials with follow-up durations extending for periods of up to 10 years. These scenarios evaluated durability and monitored functional outcomes, such as changes in the status of the visual field. Studies include conflicting results regarding the consistency of measured IOP change over many years, although some large trials described findings that did not indicate a long-term diminishing effect, or "drift." These long-term studies are associated with the limitation of participant drop-out (attrition).

Evidence in Specific Patient Groups and Uncertainty

Research has been conducted to explore use in children aged two years and older, but data for children younger than two remains insufficient. Research related to older adults addresses the complication of assessing the medicine’s full profile in patients with multiple health conditions (comorbidities). Data for long-term functional outcomes that applies uniformly across all possible populations is limited. Furthermore, some studies indicate that the measured pressure-level change may be less pronounced during nocturnal hours compared to daytime measurements.

Frequently Asked Questions (FAQ)

Common questions about Dispatim (FAQ)


Q: How quickly should I expect Dispatim to start working?

According to the clinical pharmacology data, the effect of Dispatim on eye pressure may be detected in as quickly as 30 minutes after a single dose. The maximum pressure-lowering effect is typically seen within one to two hours following administration, which is when the greatest reduction in pressure is observed.


Q: Can Dispatim be taken by people who are sensitive to gluten?

Official documentation on the composition of the eye drop solution does not typically list gluten or ingredients derived from gluten among the active or inactive components. Patients should consult with their healthcare provider or pharmacist to review the specific inactive ingredients, as formulations can vary between manufacturers.


Q: Is there a different name or brand for the medicine Dispatim?

Dispatim is a brand name for a medication whose active ingredient is Timolol maleate. Timolol is the generic name for this compound. Because the active ingredient is a well-established medicine, it is available under various brand names as well as the generic name itself.


Q: Does Dispatim have a warning about driving or operating machinery?

Official patient information notes that if visual disturbances or dizziness occur, caution should be used when driving or operating machinery. This is because the medication may cause temporary effects like dizziness or visual disturbances that could affect coordination.


Q: Are there common mild side effects of Dispatim that usually go away?

Common effects, such as temporary blurred vision, burning, stinging, or headache, may occur when starting the medication. While regulatory documents do not guarantee that these mild effects will disappear, the label suggests contacting a healthcare provider if any side effects persist or worsen.


Q: What is the risk category of Dispatim during pregnancy?

The official guidance states that the drug should generally be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Some international regulatory bodies categorize the active ingredient as Category C, which is used for drugs where animal studies show risk, and which should only be used if the potential benefit justifies the potential risk.


Q: Does Dispatim cause weight gain or loss, according to studies?

General changes in body weight are not listed as common side effects of the drug. However, sudden unexplained weight gain or swelling of the feet or lower legs is a documented sign of a serious heart-related reaction included in the product safety profile.


Q: Is it common for people to feel nauseous when starting Dispatim?

According to official patient information guides, nausea is listed as a possible side effect of Timolol eye drops. It is important to remember that not all patients experience every possible documented reaction.


Q: What is the official classification of Dispatim (e.g., controlled substance, prescription only)?

Dispatim is a prescription-only (Rx) medicine, meaning a healthcare professional must authorize its use. The active ingredient is not classified as a controlled substance under the U.S. Controlled Substances Act and is not generally associated with potential for abuse.


Q: If I have allergies, is Dispatim more likely to cause an allergic reaction?

Official precautions note that patients who have a history of serious allergic reactions, such as anaphylaxis, may have an increased risk of another such reaction occurring while using this medication.


Q: What does 'contraindicated' mean in relation to Dispatim?

When a condition is listed as a contraindication, it means the medication must not be used by a patient with that specific condition. For Dispatim, contraindications involve pre-existing conditions like severe asthma or certain heart rhythm abnormalities, where the use of the drug is associated with a specific, heightened risk.


Q: Is Dispatim known to be habit-forming or addictive?

Regulatory classification shows that Dispatim is not scheduled as a controlled substance. The medication is not generally associated with being habit-forming or having potential for dependence.


Q: Can Dispatim be split or crushed, according to the manufacturer's information?

Since Dispatim is manufactured as a liquid eye drop (topical ophthalmic solution), the instructions for solid medications like splitting or crushing tablets do not apply. The medicine is intended to be administered as a single drop into the eye.


Q: How do doctors monitor a patient’s progress while they are taking Dispatim?

Monitoring typically involves regularly measuring the patient’s intraocular pressure (IOP) to ensure the drug is effective. Because the active ingredient can be absorbed systemically, doctors may also monitor heart rate and general systemic effects, especially for individuals with certain pre-existing conditions.


Q: What is the half-life of Dispatim (factual question)?

The half-life is a scientific measurement that shows the time it takes for the amount of the drug in the body to be reduced by half. For the active ingredient, Timolol, when absorbed into the bloodstream, the plasma half-life is approximately four hours.


Q: Is Dispatim available as a generic medicine?

Yes, the active component of Dispatim, which is Timolol maleate ophthalmic solution, has been approved for use in generic versions. Therefore, the active ingredient is widely available from multiple manufacturers.


Q: Are there specific psychological side effects noted for Dispatim?

The official adverse reaction reports include nervous system and psychiatric effects. Specifically, the regulatory documentation lists depression as one of the psychological side effects that may occur in patients using the medication.


Q: Why do people sometimes stop taking Dispatim?

Reasons for discontinuing any medication are varied, but the official label specifies conditions that may require stopping the medication. Stopping the medication is indicated if a patient develops a serious side effect or is identified as having a contraindication, such as severe asthma.

How should Dispatim be stored and disposed of?

How to Store and Dispose of Dispatim

Dispatim (Timolol Ophthalmic Solution) must be stored at controlled room temperature, typically between 15 C and 25 C (59 F and 77 F). The product must be kept out of the sight and reach of children and protected from freezing and light.

Handling and Stability

The medicine must remain in its original container with the cap tightly closed. Due to risks of contamination, any unused solution must be discarded 28 days (or one month) after the bottle is first opened.

Disposal

Do not dispose of this medicine in household waste or via wastewater. Unused or expired Dispatim must be disposed of according to local pharmaceutical take-back programs or by consulting a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dispatim found in:

A-Z Index: